Trial results

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

NCT06065540 on ClinicalTrials.gov · last registry update 2026-07-08

An unusually large phase 3: 2,734 participants, more than double the 424 typical for the stage. The sponsor logged completion for 19 November 2025. Primary outcome, as filed: CagriSema (dose 1) versus semaglutide (dose 1): Change in glycated haemoglobin (HbA1c). semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P3

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

2,734

Started

2023-09-27

Primary completion

2025-11-19 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

CagriSema (dose 1) versus semaglutide (dose 1): Change in glycated haemoglobin (HbA1c)

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.